gr1802
Small moleculeexperimental
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Jul 19, 2022 (NCT06642961)
Timeline
Indications
Mechanism of action
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07199257 | Phase 3 | Sep 25, 2025 | Government of China |
| NCT07154342 | Phase 3 | Aug 15, 2025 | Government of China |
| NCT06516302 | Phase 3 | Aug 31, 2024 | Capital Medical University, Government of China |
| NCT06315426 | Phase 2 | Mar 31, 2024 | Government of China, Tongji University |
| NCT06216392 | Phase 3 | Jan 31, 2024 | Government of China |
| NCT06028490 | Phase 2 | Sep 7, 2023 | Huazhong University of Science and Technology |
| NCT06015243 | Phase 2 | Aug 18, 2023 | Government of China |
| NCT05873803 | Phase 2 | Feb 8, 2023 | Government of China |
| NCT06642961 | Phase 2 | Jul 19, 2022 | Government of China |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 8 | 8 | 2 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Tongji University | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1